-transparent.png){kind=logo}
Although IAPP was first discovered and isolated from amyloid deposits in an endocrine pancreatic tumour (EPT), surprisingly few reports have investigated the potential use of IAPP as a marker for neuroendocrine tumour growth. In this study we present results from plasma measurements of IAPP in 102 patients with neuroendocrine tumours. Four of 35 patients (11%) with midgut carcinoid tumours, but none of the patients (4 and 5, respectively) with lung carcinoids or with rectal carcinoids displayed elevated plasma levels of IAPP. Five of 31 patients (16%) with sporadic EPT and 3 of 27 patients (11%) with EPT and multiple endocrine neoplasia type 1 syndrome disclosed elevated IAPP levels. Within the different syndromes, 1/11 individuals with insulinoma, 2/16 with gastrinoma, 0/2 with glucagonoma, 0/3 with VIPoma and 5/26 with non-functioning tumours showed elevated plasma levels of IAPP. In two patients, the plasma IAPP levels were extremely elevated. These patients also exhibited altered glucose homeostasis. In response to a standardised mixed meal test, IAPP increased in parallel to the insulin, pancreatic polypeptide, gastrin and glucose responses. In MEN1 patients with hypercalcaemia due to increased secretion of parathyroid hormone, the plasma levels of IAPP were significantly higher before than after surgical removal of the parathyroid adenomas. However in normocalcaemic patients, no correlation between the blood calcium and plasma IAPP levels was found. Immunocytochemical staining of tumour tissue showed that 9/13 (69%) of insulin producing tumours, 4/14 (29%) of non-functioning tumours and 1/9 (11%) of gastrin producing tumours were IAPP immunoreactive. Amyloid deposits were always IAPP immunoreactive. In conclusion, increased circulating levels of IAPP occurred in 12% of 102 patients with neuroendocrine tumours. In 2 patients with extremely elevated plasma levels of IAPP, effects on glucose homeostasis were recorded. Thus, IAPP may be useful as an additional marker for neuroendocrine tumour growth in selected cases.
M Stridsberg, and
B Eriksson, and
G Lundqvist, and
B Skogseid, and
E Wilander, and
K Oberg
August 2005,
Nihon rinsho. Japanese journal of clinical medicine,
M Stridsberg, and
B Eriksson, and
G Lundqvist, and
B Skogseid, and
E Wilander, and
K Oberg
January 1991,
Acta oncologica (Stockholm, Sweden),
M Stridsberg, and
B Eriksson, and
G Lundqvist, and
B Skogseid, and
E Wilander, and
K Oberg
January 1992,
Diabetes research and clinical practice,
M Stridsberg, and
B Eriksson, and
G Lundqvist, and
B Skogseid, and
E Wilander, and
K Oberg
January 2014,
Current Alzheimer research,
M Stridsberg, and
B Eriksson, and
G Lundqvist, and
B Skogseid, and
E Wilander, and
K Oberg
December 2000,
Molecular medicine (Cambridge, Mass.),
M Stridsberg, and
B Eriksson, and
G Lundqvist, and
B Skogseid, and
E Wilander, and
K Oberg
January 1992,
Diabetes research and clinical practice,
M Stridsberg, and
B Eriksson, and
G Lundqvist, and
B Skogseid, and
E Wilander, and
K Oberg
September 1989,
Diabetes research and clinical practice,
M Stridsberg, and
B Eriksson, and
G Lundqvist, and
B Skogseid, and
E Wilander, and
K Oberg
June 1997,
Wiener klinische Wochenschrift,
M Stridsberg, and
B Eriksson, and
G Lundqvist, and
B Skogseid, and
E Wilander, and
K Oberg
April 1999,
Journal of molecular biology,
M Stridsberg, and
B Eriksson, and
G Lundqvist, and
B Skogseid, and
E Wilander, and
K Oberg
February 2013,
Biochemistry,
